Mitigating the cardiovascular and renal effects of NSAIDs.

OBJECTIVE Nonsteroidal anti-inflammatory drugs (NSAIDs) are principal pharmacologic agents for symptom relief in patients with arthritis and other inflammatory conditions. Cardiovascular risk is associated with all NSAIDs, excluding aspirin. Selective inhibition of cyclo-oxygenase-2 (COX)-2 could produce a relative reduction in endothelial production of prostacyclin, while leaving the platelet production of thromboxane A2 (TXA2 ) intact. It has been speculated that this imbalance of homeostatic prostanoids might increase the risk for thrombotic events. The goal of this review is to provide physicians guidelines to mitigate cardiovascular and nephrotoxicity of NSAIDs. METHODS We conducted a systematic literature review to determine what information is available to guide treatment decisions in this patient population. RESULTS Selective inhibition of COX-2 could produce a relative reduction in endothelial production of prostacyclin, while leaving the platelet production of TXA2 intact. Increasing degrees of selectivity for COX-2 are associated with augmented cardiovascular risk, whereas increasing degrees of selectivity for cyclo-oxygenase-2 (COX-1) are associated with augmented gastrointestinal risk. Some NSAIDs (such as ibuprofen) can interfere with the cardioprotective effects of aspirin by competitively binding to COX-1 enzyme, resulting in increased TXA2 production Naproxen may differ from other NSAIDs in sustaining functionally important degrees of inhibition of platelet cyclooxygenase-1 activity throughout the dosing interval. CONCLUSION It is of paramount importance to consider individual health factors when choosing therapy with NSAIDs.

[1]  L. Navar,et al.  The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function , 2012, Current opinion in nephrology and hypertension.

[2]  H. Seyberth,et al.  Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. , 1997, The American journal of physiology.

[3]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[4]  Á. Lanas,et al.  Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis , 2011, BMC medicine.

[5]  L. Køber,et al.  Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study , 2011, Circulation.

[6]  R. Day,et al.  Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. , 1996, The Journal of rheumatology.

[7]  C. Helmick,et al.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.

[8]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[9]  E. Antman,et al.  Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.

[10]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[11]  J. Sluijter,et al.  Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig , 2007, Circulation.

[12]  R. Barkin,et al.  Should Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) be Prescribed to the Older Adult? , 2010, Drugs & aging.

[13]  M. Gimbrone,et al.  Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[15]  R. de Caterina,et al.  Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease , 2006, Clinical pharmacology and therapeutics.

[16]  L. G. García Rodríguez,et al.  Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. , 2008, Journal of the American College of Cardiology.

[17]  G. Davı̀,et al.  Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.

[18]  R. Barkin,et al.  Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. , 2001, Southern medical journal.

[19]  M. Gold,et al.  Systemic Bioavailability of Topical Diclofenac Sodium Gel 1% Versus Oral Diclofenac Sodium in Healthy Volunteers , 2010, Journal of clinical pharmacology.

[20]  A. Whelton,et al.  Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.

[21]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. , 2008, Osteoarthritis and cartilage.

[22]  B. Gertz,et al.  Renal Effects of COX-2-Selective Inhibitors , 2001, American Journal of Nephrology.

[23]  A. Ríos,et al.  Cyclooxygenase-2 and kidney failure. , 2012, Prostaglandins & other lipid mediators.

[24]  A. Buvanendran,et al.  Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. , 2004, American journal of therapeutics.

[25]  C. Patrono,et al.  Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[26]  S. Iacobelli,et al.  Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.

[27]  A. Whelton,et al.  Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. , 2000, American journal of therapeutics.

[28]  T. Macdonald,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[29]  D. Fitzgerald,et al.  Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. , 2004, Journal of the American College of Cardiology.

[30]  F. Gengo,et al.  Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis , 2008, Journal of clinical pharmacology.

[31]  G. Minno,et al.  Monitoring the entry of new platelets into the circulation after ingestion of aspirin. , 1983, Blood.

[32]  Joseph Loscalzo,et al.  Cyclooxygenase inhibition and cardiovascular risk. , 2005, Circulation.

[33]  Edward E Knaus,et al.  Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. , 2008, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[34]  D. Powell,et al.  Pharmacokinetics of ibuprofen in febrile children , 2004, European Journal of Clinical Pharmacology.

[35]  C. Vio,et al.  E Prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. , 2009, Biochemical and biophysical research communications.

[36]  J. Scheiman,et al.  Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. , 2001, The American journal of medicine.

[37]  B. Jugdutt.  Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. , 2007, Circulation.

[38]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[39]  Elie Karam,et al.  Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. , 2008, The journal of pain : official journal of the American Pain Society.

[40]  B. Gertz,et al.  Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[41]  G. FitzGerald,et al.  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.

[42]  D. Mukherjee.  Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? , 2006, Thrombosis and Haemostasis.

[43]  S. Roth,et al.  The NSAID Dilemma: Managing Osteoarthritis in High-Risk Patients , 2011, The Physician and sportsmedicine.

[44]  J. Schnermann,et al.  Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. , 2007, American journal of physiology. Renal physiology.

[45]  C. Furberg.  The COX-2 inhibitors--an update. , 2006, American heart journal.

[46]  G. Herrero-Beaumont,et al.  EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2005, Annals of the rheumatic diseases.

[47]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[48]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[49]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.